A blog about chemistry, drug development, science, and technology
The Washington Post has a story today on a bird flu vaccine being tested by Sanofi Pasteur.
Bird Flu Vaccine May Hit Many Strains - washingtonpost.com:
The key point appears to be that the specific strain this vaccine was based on from Vietnam, shows cross protection against other strain of the H5N1 from other countries. While this is interesting, it does not guarantee immunity against all H5N1 strains. Indeed it is good to see and emphasize that the researchers state it is very early and they still don’t know enough to make blanket statements about cross protection.
Another point made in the article is that stockpiling vaccine may be an effective approach. However, it is still risky since it is unknown if the next pandemic will even be H5 based. It might very well end up that we are concentrating on the wrong virus; it is impossible to predict which virus could lead to the next pandemic.
Other Resources
• InteliHealth: Bird Flu Vaccine May Hit Many Strains
• Bird flu vaccine may be more protective than thought; Swiss to stockpile | Markets | Headline News | Canadian Business Online
• Sanofi bird flu vaccine may offer wider protection
Technorati Tags: avian flu, bird flu, pandemic flu, Sanofi-Aventis, Sanofi
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 0.948 seconds